naltrexone has been researched along with Muscle Weakness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S | 1 |
| Bagherzadeh, AH; Ebrahimi-Dariani, N; Farahvash, MJ; Farhangi, E; Froutan, H; Ghofrani, H; Mansour-Ghanaei, F; Mirmomen, S; Nasiri-Toosi, M; Pourrasouli, Z; Taheri, A | 1 |
1 trial(s) available for naltrexone and Muscle Weakness
| Article | Year |
|---|---|
Effect of oral naltrexone on pruritus in cholestatic patients.
Topics: Administration, Oral; Adult; Aged; Cholestasis; Dizziness; Headache; Humans; Middle Aged; Muscle Weakness; Naltrexone; Nausea; Pain Measurement; Placebos; Pruritus; Single-Blind Method; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2006 |
1 other study(ies) available for naltrexone and Muscle Weakness
| Article | Year |
|---|---|
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Animal; Drug Combinations; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Muscle Weakness; Myelin Proteins; Naltrexone; Neural Conduction; Phosphatidylinositol 3-Kinases; Proof of Concept Study; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Schwann Cells; Signal Transduction; Sorbitol | 2019 |